Download PDF
Thromb Haemost 1993; 70(05): 858-863
DOI: 10.1055/s-0038-1649683
Fibrinolysis
Schattauer GmbH Stuttgart

Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1)

P J Declerck
1   The Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
,
H Moreau
1   The Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
,
J Jespersen
2   The Section of Coagulation and Fibrinolysis, Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark
,
J Gram
2   The Section of Coagulation and Fibrinolysis, Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark
,
C Kluft
3   The IVVO TNO Gaubius Laboratory, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 16 December 1992

Accepted after revision 17 May 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In order to evaluate the comparability of data obtained with various available kits for the immunological determination of PAI-1 antigen in plasma and in order to investigate the underlying cause of observed differences, e. g. problems of specificity or of proper calibration of the provided standard, a multicenter study was organised in the framework of the Subcommittee of Fibrinolysis of the Scientific and Standardization Committee.

Eight different plasma samples were distributed among 16 laboratories: a pooled normal plasma, NIBSC 87/512, PAI-1 antigen depleted plasma, PAI-1 depleted plasma supplemented with 59 ng/ml active PAI-1 and four different individual plasma samples. A considerable variation in absolute values is observed between the various kits, e.g. in pooled normal plasma a value is found ranging between 7.4 and 28 ng/ml. Harmonization of all data relative to the PAI-l-depleted plasma supplemented with an exact amount of active PAI-1 (59 ng/ml), followed by a statistical analysis using a two way analysis of variance, revealed that 6 out of 7 kits yielded values that were not significantly different with coefficients of variation around 30%. Correlations between the values obtained with these kits yielded slopes between 0.75 and 1.44 with correlation coefficients between 0.973 and 0.999. Values obtained with one kit appeared to be significantly different (even after harmonization) from the other kits (p <0.001 to p <0.05). Comparison of PAI-1 antigen with the PAI activity values in the analysed samples suggests that one kit may deal with a problem of a difference in reactivity between active and latent PAI-1.

In conclusion 6 different kits yield results that, only after harmonization, are comparable and do correlate very well. Thus proper calibration of the provided standards may solve the majority of the problems observed with PAI-1 antigen kits. Differential specificity towards different conformational forms of PAI-1, as a consequence of the use of different monoclonal antibodies, is a minor, but a potential problem, that needs to be considered when comparing data obtained with various methods.

 

  • References

  • 1 Paramo JA, Colucci M, Collen D, Van deWerf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
    CrossrefPubMedGoogle Scholar
  • 2 Hamsten A, Wiman B, De FaireU, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 3 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip JoetC, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep vein thrombosis. Thromb Haemostas 1987; 57: 067-072
    PubMedGoogle Scholar
  • 4 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
    PubMedGoogle Scholar
  • 5 Lambers JWJ, Cammenga M, Koenig BW, Martens K, Pannekoek H, van MourikJA. Activation of human endothelial cell-type plasmino gen activator inhibitor (PAI-1) by negatively charged phospholipides. J Biol Chem 1987; 262: 17492-17496
    PubMedGoogle Scholar
  • 6 Vaughan DE, Declerck PJ, Van HoutteE, De MolM, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circulation Res 1990; 67: 1281-1286
    CrossrefPubMedGoogle Scholar
  • 7 Declerck PJ, De MolM, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696
    PubMedGoogle Scholar
  • 8 Gram J, Declerck PJ, Sidelman J, Jespersen J, Kluft C. Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. Thromb Haemostas 1993; 70: 852-857
    PubMedGoogle Scholar
  • 9 Urdén G, Johansson U, Chmielewska J, Brandt J, Wiman B. Monoclonal antibodies towards the fast inhibitor of tissue plasminogen activator from human plasma and serum. Thromb Haemostas 1986; 55: 383-387
    PubMedGoogle Scholar
  • 10 Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang JY, Kristensen P, Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells – Inhibitor neutralization and one-step affinity purification. Thromb Haemostas 1986; 55: 206-212
    PubMedGoogle Scholar
  • 11 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 12 Booth NA, Macgregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterisation. Eur J Biochem 1987; 165: 595-600
    CrossrefPubMedGoogle Scholar
  • 13 Urden G, Chmielewska J, Carlsson T, Wiman B. Immunological relationship between plasminogen activator inhibitors from different sources. Thromb Haemostas 1987; 57: 029-034
    PubMedGoogle Scholar
  • 14 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme- linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 15 Lund LR, Georg B, Nielsen LS, Mayer M, Danø K, Andreasen PA. Plasminogen activator inhibitor type 1: cell-specific and differentition-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Mol Cell Endocrinol 1988; 60: 043-053
    CrossrefPubMedGoogle Scholar
  • 16 Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-332
    PubMedGoogle Scholar
  • 17 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
    CrossrefPubMedGoogle Scholar
  • 18 MacGregor IR, Booth NA. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminoen activator inhibitor (PAI-1). Thromb Haemostas 1988; 59: 068-072
    PubMedGoogle Scholar
  • 19 Rijken DC, Sprengers ED, Van de, Hoeven RJ, Kluft C, Engesser L. Plasminogen activator inhibitor 1 (PAI-1) antigen levels in human plasma samples. Fibrinolysis 1988; 2 (Suppl. 02) 079-082
    PubMedGoogle Scholar
  • 20 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-1752
    CrossrefPubMedGoogle Scholar
  • 21 Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res 1990; Suppl X: 003-009
    PubMedGoogle Scholar
  • 22 Declerck PJ, Verstreken M, Collen D. Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990; 4 (Suppl. 02) 132-133
    PubMedGoogle Scholar
  • 23 Kluft C, Jie AFH. Comparison of specificities of antigen assays for plasminogen activator inhibitor 1 (PAI-1). Fibrinolysis 1990; 4 (Suppl. 02) 136-137
    PubMedGoogle Scholar
  • 24 Huisman LGM, Meijer P, van GriensvenJ, Kluft C. Evaluation of the specificity of antigen assays for plasminogen activator inhibitor 1: comparison of two new commercial kits. Fibrinolysis 1992; 6 (Suppl. 03) 087-088
    PubMedGoogle Scholar
  • 25 Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 1990; 60: 509-516
    CrossrefPubMedGoogle Scholar
  • 26 Declerck PJ, De MolU, Alessi HC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-15461
    PubMedGoogle Scholar
  • 27 Andreotti D, De BortACW, Regan T, Maseri A, Kluft C. Factors affecting the relation between plasminogen activator inhibitor (PAI) activity and PAI-1 antigen levels in normals and patients with arterial disease. Fibrinolysis 1990; 4 (Suppl. 02) 134-135
    PubMedGoogle Scholar
  • 28 Alessi MC, Juhan-Vague I, Declerck PJ, Collen D. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. Thromb Res 1991; 62: 275-285
    CrossrefPubMedGoogle Scholar